BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the 36th Annual Piper Sandler Healthcare Conference, taking place in New York, NY on December 3-5, 2024.
| 36th Annual Piper Sandler Healthcare Conference | |
| Date: | Tuesday, December 3, 2024 |
| Time: | 11:00AM ET |
| Format: | Fireside Chat |
| Location: | Lotte New York Palace, New York |
| Webcast Link | |
This live webcast will also be accessible through “events & presentations” page of the investors section of X4 Pharmaceuticals’ website. After the conclusion of the conference, a replay of this webcast will be available through the same link.
The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Piper Sandler representative to request meetings.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
(617) 430-7576
| Last Trade: | US$2.72 |
| Daily Change: | -0.42 -13.34 |
| Daily Volume: | 1,814,925 |
| Market Cap: | US$19.540M |
August 12, 2025 June 10, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
